Rani Minority Interest vs Operating Income Analysis
| RANI Stock | USD 1.39 0.01 0.71% |
Rani Therapeutics financial indicator trend analysis is much more than just breaking down Rani Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Rani Therapeutics is a good investment. Please check the relationship between Rani Therapeutics Minority Interest and its Operating Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Minority Interest vs Operating Income
Minority Interest vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Rani Therapeutics Minority Interest account and Operating Income. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Rani Therapeutics' Minority Interest and Operating Income is -0.1. Overlapping area represents the amount of variation of Minority Interest that can explain the historical movement of Operating Income in the same time period over historical financial statements of Rani Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of Rani Therapeutics' Minority Interest and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Minority Interest of Rani Therapeutics Holdings are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Minority Interest i.e., Rani Therapeutics' Minority Interest and Operating Income go up and down completely randomly.
Correlation Coefficient | -0.1 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Minority Interest
Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Rani Therapeutics Holdings whose combined shares represent less than 50% of the total outstanding shares issued by Rani Therapeutics have a minority interest in Rani Therapeutics.Operating Income
Operating Income is the amount of profit realized from Rani Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Rani Therapeutics Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Rani Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Rani Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. The Rani Therapeutics' current Tax Provision is estimated to increase to about (35.1 K). The current Selling General Administrative is estimated to decrease to about 19.7 M
| 2022 | 2023 | 2024 | 2025 (projected) | Depreciation And Amortization | 1.3M | 822K | 945.3K | 925.5K | Interest Income | 1.2M | 3.4M | 4.0M | 4.2M |
Rani Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Rani Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rani Therapeutics fundamental ratios Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 79.4M | 124.2M | 108.0M | 57.9M | 66.6M | 86.4M | |
| Other Current Liab | 695K | 1.6M | 1.3M | 1.7M | 1.6M | 1.4M | |
| Total Current Liabilities | 5.3M | 2.6M | 4.8M | 8.0M | 9.2M | 5.3M | |
| Total Stockholder Equity | (113.3M) | 47.4M | 36.9M | 12.9M | 14.8M | 15.5M | |
| Property Plant And Equipment Net | 4.5M | 4.6M | 7.1M | 6.8M | 7.8M | 6.0M | |
| Net Debt | (69.3M) | (117.5M) | 3.2M | 24.2M | 21.8M | 22.9M | |
| Retained Earnings | (114.0M) | (8.3M) | (38.9M) | (72.9M) | (83.8M) | (88.0M) | |
| Accounts Payable | 537K | 1.1M | 1.5M | 648K | 745.2K | 863.1K | |
| Cash | 73.1M | 117.5M | 27.0M | 5.9M | 5.3M | 5.0M | |
| Non Current Assets Total | 4.5M | 4.6M | 7.1M | 7.1M | 8.1M | 6.5M | |
| Cash And Short Term Investments | 73.1M | 117.5M | 98.5M | 48.5M | 55.8M | 77.9M | |
| Liabilities And Stockholders Equity | 79.4M | 124.2M | 108.0M | 57.9M | 66.6M | 86.4M | |
| Non Current Liabilities Total | 187.4M | 1.1M | 29.2M | 24.5M | 22.0M | 20.9M | |
| Other Current Assets | 167K | 2.1M | 2.4M | 2.3M | 2.7M | 1.6M | |
| Total Liab | 192.8M | 2.6M | 34.0M | 32.5M | 29.2M | 27.8M | |
| Net Invested Capital | (109.6M) | 47.4M | 66.0M | 42.2M | 48.6M | 51.0M | |
| Property Plant And Equipment Gross | 6.3M | 6.9M | 7.1M | 10.5M | 12.1M | 8.0M | |
| Total Current Assets | 74.9M | 119.6M | 100.9M | 50.8M | 58.5M | 79.9M | |
| Accumulated Other Comprehensive Income | (849.0K) | (124.2M) | (73K) | (12K) | (13.8K) | (14.5K) | |
| Net Working Capital | 69.6M | 117.0M | 96.1M | 42.9M | 49.3M | 74.6M |
Currently Active Assets on Macroaxis
When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.